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Abstract
Purpose It is unknown whether positive psychological changes (e.g., in life perspective, self-perception, and social relationships)
after being diagnosed with ovarian cancer can reduce anxiety and depression in patients and their partners. The first aim of the
present study was to assess differences in anxiety and depression between patients diagnosed with an ovarian tumor and their
partners. The second aim was to explore the mutual associations of patients’ and partners’ posttraumatic growth and their anxiety
and depressive symptoms.
Methods Participants included 130 Dutch couples of which one partner was diagnosed with a borderline ovarian tumor or
ovarian cancer between 2000 and 2010, as registered by the Netherlands Cancer Registry. In September 2011, a questionnaire
was sent including the Hospital Anxiety and Depression Scale (anxiety and depression) and Cancer Survivors (Partners) Unmet
Needs measure (positive psychological changes).
Results A one-way multivariate analysis of variance showed that patients reported higher anxiety than partners, without differ-
ences in depression. Contrasting to our expectations, an actor-partner interdependence model revealed no mutual dyadic asso-
ciations between positive psychological changes and anxiety or depressive symptoms.
Conclusions Based on these findings, positive psychological change seems to be an independent construct unrelated to anxiety or
depression in couples diagnosed with ovarian tumors. Still, as ovarian tumor patients and partners suffer from high anxiety and
depression, further research investigating how these feelings can be reduced in couples dealing with an ovarian tumor is necessary.
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Background
Ovarian tumors can be distinguished in borderline ovarian
tumors and ovarian cancer. Borderline tumors of the ovary
(also called tumors of low-malignant potential) are a
heterogeneous group of lesions defined histologically by atyp-
ical epithelial proliferation without stromal invasion.
Borderline ovarian tumors are mostly diagnosed at an earlier
stage, resulting in an excellent prognosis with a 5-year surviv-
al of 98%, while in contrast, ovarian cancer has an overall 5-
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year survival of 38–46% [1–3]. Due to the poor prognosis of
ovarian cancer, patients and their loved ones are prone to
psychological problems such as anxiety and depression after
diagnosis [4–6]. For borderline ovarian tumors, evidence on
the psychological burden is lacking, although it is known pa-
tients correlate the malignant potential of their tumor close to
that of ovarian cancer even though they are aware their prog-
nosis is more favorable [7].
Caregivers of cancer patients are just as likely as patients to
suffer from psychological distress, including negative affect
[8]. It is unclear if there are any differences between ovarian
tumor patients and partners in experienced anxiety or depres-
sion. Several studies in gynecological and breast cancer pa-
tients and partners reported that partners of female cancer
patients experience higher levels of negative affect, including
depression, anxiety, phobic anxiety, and overall distress than
patients themselves [8–10]. In contrast, a meta-analysis
showed female patients report more psychological stress than
their partners [11]. This meta-analysis included few studies
involving gynecological cancers (9%) and few studies cover-
ing patients with advanced stage cancers (8%), which results
in too little clarity to draw conclusions on differences in ex-
perienced anxiety and depression between ovarian tumor pa-
tients and partners.
Although being diagnosed with cancer often leads to anx-
iety and depression, patients can also experience positive psy-
chological changes following a cancer diagnosis [12]. Positive
psychological changes are often measured as posttraumatic
growth (PTG), which is defined as Bpositive psychological
change experienced as a result of the struggle with highly
challenging life circumstances^ [13]. It includes benefits such
as positive changes in self-perception (e.g., viewing oneself as
mentally stronger and as more capable to cope with problems
in the future), social relationships (e.g., feeling more connect-
ed to others, knowing who one’s real friends are), and life
perspective (e.g., being more appreciative of the small things
in life, finding greater meaning in intrinsically important pri-
orities) [14]. Between 53 and 90% of cancer patients report to
experience some level of PTG [12, 15, 16]. Moreover, cancer
patients who experience PTG generally tend to report higher
levels of positive affect and lower levels of negative affect
than patients who do not experience PTG [17, 18]. Similarly,
partners of ovarian tumor patients might experience positive
psychological changes as well. Two studies, of which one
involving couples suffering from various forms of cancer
and one including gynecological cancer couples exclusively,
found couples experience similar levels of PTG, indicating
patients share their psychological growth with their partners
[19, 20].
So far, there are no published data on the association of
positive psychological changes and anxiety and depression
of ovarian tumor couples. The current study aims to assess
(1) differences between patients and partners with ovarian
cancer and borderline ovarian tumors in severity of anxiety
and depression, (2) differences in anxiety and depression of
patients with ovarian cancer and borderline ovarian tumors,
and (3) the association between positive psychological chang-
es and anxiety and depression on patients and partners, and
their mutual influence. This involves analyzing the direct ef-
fects of one’s positive psychological changes on their anxiety
and depression and the mutual effects of one’s positive psy-
chological changes on their partner’s anxiety and depression.
Since the literature shows conflicting conclusions about anx-
iety, depression, and positive psychological changes among
couples suffering from ovarian tumors, no hypotheses are
formed.
Methods
Design, setting, and participants
In this population-based cross-sectional study, participants
were diagnosed with ovarian cancer or a borderline ovarian
tumor between 1 January 2000 and 1 July 2010 as registered
in the Netherlands Cancer Registry (NCR). Ethical approval
for the study was obtained from the Medical Ethics
Committee of the Elisabeth-TweeSteden Hospital.
Data collection
In September 2011, 719 women diagnosed with an ovarian
tumor were invited to participate via their gynecologists
(Fig. 1). Participants received a letter and paper questionnaires
from their (ex-)attending specialist. Two questionnaires had
been sent to them: one version for the ovarian tumor patient
and one version for their partner. By returning the question-
naire, they provided informed consent. The data collection
was done within PROFILES (Patient Reported Outcomes
Following Initial treatment and Long term Evaluation of
Survivorship), a registry for studies on the physical and psy-
chosocial impact of cancer and its treatment from a dynamic,
growing population-based cohort of cancer survivors [21].
PROFILES is linked directly to the NCR. In 2012, 130 cou-
ples completed both the patient and partner questionnaires (90
ovarian, 40 borderline ovarian) (Fig. 1).
Clinical and sociodemographic characteristics
Clinical information (i.e., date of birth, date of diagnosis,
stage, grade) and information about socioeconomic status
were obtained from the NCR [22]. Further sociodemographic
information (i.e., gender of partner, marital status, education)
was collected from the questionnaires. Comorbidity at the
time of survey was assessed with the adapted Self-
administered Comorbidity Questionnaire [23].
424 Support Care Cancer (2019) 27:423–431
Instruments
The Dutch translation of the Hospital Anxiety and Depression
Scale (HADS) was used to determine the amount of anxiety
and depressive symptoms [24]. Participants responded to sev-
en anxiety items and seven depression items referring to cur-
rent feelings on a 4-point scale. The HADS is deemed a highly
reliable screening instrument for Dutch somatically ill patients
to determine distress (Cronbach’s alpha = .90) [25]. However,
among caregivers of cancer patients, the total HADS (the
combination of the anxiety and depression subscales) is not
supported to measure distress [26], and the unidimensional
anxiety and depression scales are considered more valid as
separate scales, with Cronbach’s alpha values of .90 and .86,
respectively [26]. Since the following study included both
cancer patients and partners, anxiety and depression were in-
cluded in analyses as separate constructs.
Additionally, the six positive outcome items of CaS(P)UN
(Cancer Survivors (Partners) Unmet Needs measure) were
included to measure positive psychological changes, also in-
dicated as benefit-finding and posttraumatic growth [27].
CaSUN items were included in the patient questionnaire.
CaSPUN items were included in the partner questionnaire.
CaS(P)UN items offer four response options (Byes, but I have
always been like this,^ Byes, this has been a positive
outcome,^ Bno, and I would like help to achieve this,^ or
Bno, and this is not important to me^). Sensitivity analyses
on each individual CaS(P)UN item for anxiety and depression
showed similar effects across all CaS(P)UN items as none of
the items predicted anxiety or depression for patients or part-
ners. Therefore, for each patient, the total number of times the
option Byes, this has been a positive outcome^ on each of the
six questions was computed and taken as indication of the
level of experienced positive psychological changes. Thus,
PTG was transformed into a sum variable with a range from
0 to 6. The content of the items within the questionnaires for
patient and partner were identical. Although no research has
been done on the validation of the six positive outcome items
of CaS(P)UN for measuring PTG, the items were still used
since no other specific measurement of PTG experienced by
partners was found and Hodgkinson et al. [27] implied PTG
and positive psychological changes are similar concepts.
Statistical analyses
Statistical analyses were performed using SPSS Statistics
22.0. Two-sided p values lower than .05 were considered sig-
nificant unless specified otherwise. To determine the required
number of participating couples, a post hoc power analysis
was performed using G*Power 3.1.9.2. The necessary n is
measured by using Blinear multiple regression: fixed model,
R2 deviation from zero^ as the statistical test used concerning
Fig. 1 Number of included
participants (couples: total n =
130)
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the second research question. The following settings were
used: medium effect size = .15,α error probability = .05, pow-
er (1 − β error probability) = .95, and number of predictors =
2. Results showed 107 couples are required to reach the pre-
ferred power level. The current study used more than 107
couples (n = 130) accounting for missing values.
First, descriptive statistics were calculated for the
sociodemographic, medical, and psychological data of ovari-
an tumor patients and partners and were described by means,
standard deviations, and percentages. Anxiety and depression
tend to be comorbid [28], thus predicting a high interdepen-
dency level between anxiety and depression. Therefore, a one-
way multivariate analysis of variance (MANOVA) was per-
formed to answer the first research question, since this proce-
dure (1) examines mean differences between the dependent
variables while accounting for their interdependency, (2)
shows the relationship between anxiety and depression rather
than examining each of them in isolation, and (3) prevents the
risk of an inflated type 1 error, which could be caused if two
separate univariate analyses of variance (ANOVAs) were per-
formed on anxiety and depression [29, 30]. By performing a
MANOVA with two dependent variables, it is necessary to
apply a Bonferroni adjusted alpha level of .025 [31].
Analyses were adjusted for age as a possible confounder.
The second research question involved whether symptoms
of anxiety and depression in patients and partners are associ-
ated with positive psychological changes. A multilevel model
in the form of a two-intercept model, the actor-partner inter-
dependence model (APIM), was used. The multilevel model
takes into account the correlation of patient and partner data
[32]. Additionally, by applying the APIM, it is possible to
calculate the effect of one’s independent variable on their
own dependent variable (i.e., actor effect), as well as the effect
of one’s independent variable on the dependent variable of
their partner (i.e., partner effect) [33]. All continuous variables
were centered on the sample mean. All dichotomous variables
were coded as 1 and − 1. The APIM was performed with a
heterogeneous compound symmetry (HCS) as we assumed
patients and partners are distinguishable members within their
dyad with equal influence on each other [32].
The two-intercept model involves dropping the ordi-
nary intercept from the model in order to include two
dummy variables as intercepts [32]. The following two
dummy variables were created: patient (patient = 1, part-
ner = 0) and partner (patient = 0, partner = 1). The dummy
variables corresponded to the individual intercepts for
each of the patient and partner variables. The separate
predictor variables for patients and partners were created
by multiplying the dummy variables with the positive
psycho log ica l changes exper ienced by pa t i en t
(PatientPTG) and the positive psychological changes ex-
perienced by partner (PartnerPTG). This resulted in the
following regression equations: [Anxiety = Patient +
Partner + PatientPTG + PartnerPTG] and [Depression =
Patient + Partner + PatientPTG + PartnerPTG].
Consequently, a single model showed the effect of both
patient and partner PTG on patient- and partner-dependent
variables (either anxiety or depression). In total, two
models were created: one with anxiety and one with de-
pression as the dependent variable. We combined ovarian
cancer and borderline ovarian tumors for these analyses as
we did not expect the association between positive psy-
chological changes and anxiety and depression to be dif-
ferent between these tumor types and because we had a
sufficient sample size for the analyses.
Results
Patients and partners
Ovarian cancer patients were on average 61 years of age, and
their partners were on average 63. Borderline ovarian tumor
patients were on average 57 years of age, and their partners
were on average 60 (Table 1). On average, patients were di-
agnosed with an ovarian tumor 6 years prior to questionnaire
completion.
Anxiety and depression
Patients and partners reported different levels of their com-
bined anxiety and depression score (Table 2). Further inspec-
tion showed a statistical difference for anxiety (Wilks’ lamb-
da = .04; p = .01). Patients reported higher levels of anxiety
(M = 5.6, SD = 3.7) than partners (M = 4.4, SD = 3.6). This
difference is mainly attributable to ovarian cancer patients
(M = 6.0; SD = 3.8) and their partners (M = 4.6, SD = 3.6).
No differences were found on depression between patients
(M = 4.0, SD = 4.2) and partners (M = 3.9, SD = 3.5).
For borderline ovarian tumors, there were no differences on
anxiety or depression between patients (resp. M = 4.8, SD =
3.4; M = 3.5, SD = 3.9) and partners (M = 4.1, SD = 3.5; M =
2.7, SD = 2.8).
Comparing couples based on diagnosis, results showed
partners of patients with ovarian cancer reported higher levels
of depression (M = 4.4, SD = 3.6) than partners of patients
with a borderline ovarian tumor (M = 2.7, SD = 2.8).
Positive psychological changes
There were no significant actor or partner effects found be-
tween patients’ or partners’ positive psychological changes
and patients’ and partners’ anxiety or depression (Fig. 2).
Besides using the sum score for positive psychological chang-
es, sensitivity analyses including each individual CaS(P)UN item
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were conducted, showing similar results as none of the items
predicted anxiety or depression for patients or partners.
Table 1 Characteristics of
couples dealing with ovarian
tumors (n = 130)
Ovarian cancer (n =
90)
Borderline ovarian tumor
(n = 40)
Patient Partner Patient Partner
Age (mean, SD) 62.3 (10.4) 64.1 (9.7) 57.4 (12.4) 59.2 (12.4)
Gender (n (%))
Male 87 (98) 35 (92)
Female 90 (100) 2 (2) 40 (100) 3 (8)
Marital status (n (%))
Married or living together 86 (99) 39 (100)
Divorced or separated 1 (1)
Educational level (n (%))
University or higher education 14 (16) 20 (22) 9 (23) 15 (40)
Secondary vocational education 36 (41) 46 (51) 19 (49) 11 (30)
Secondary education 30 (33) 18 (20) 9 (23) 3 (8)
Primary education 8 (9) 6 (7) 2 (5) 8 (22)
Socioeconomic status (n (%))
High 31 (35) 12 (31)
Medium 43 (48) 21 (54)
Low 15 (17) 6 (15)
Years since diagnosis (mean, SD) 5.6 (3.0) 6.1 (2.7)
FIGO stage at diagnosis (n (%))
I (disease is limited to the ovaries) 50 (56)
II (disease has spread to the pelvis) 16 (18)
III (disease has spread to the abdomen) 19 (21)
IV (disease involves distant organs) 4 (4)
Unknown 1 (1)
Differentiation grade (ovarian cancer) (n (%))
Well 15 (17)
Moderate 18 (20)
Poor 26 (29)
Unknown 31 (34)
Anxiety (mean, SD) 6.0 (3.9) 4.6 (3.6) 4.8 (3.4) 4.1 (3.5)
Depression (mean, SD) 4.2 (4.3) 4.4 (3.6) 3.6 (3.9) 2.7 (2.8)
Positive change items (mean, SD)
I have benefited from contact with other cancer survivors
and/or their families
0.1 (0.3) 0.1 (0.3) < 0.1 (0.2) < 0.1 (< 0.1)
I focus more on things that are important 0.3 (0.5) 0.3 (0.4) 0.3 (0.5) 0.2 (0.4)
I realize how precious life is 0.4 (0.5) 0.3 (0.5) 0.3 (0.5) 0.1 (0.4)
I have made lots of positive changes in my life 0.3 (0.4) 0.3 (0.5) 0.3 (0.5) 0.1 (0.4)
I have grown as a person 0.4 (0.5) 0.3 (0.4) 0.2 (0.4) 0.3 (0.4)
I appreciate my relationships with others more 0.3 (0.5) 0.3 (0.4) 0.3 (0.4) 0.2 (0.4)
At least 1 positive change item (n (%)) 46 (58) 44 (51) 15 (43) 12 (33)
Sum score of positive change items (mean, SD) 1.8 (2.0) 1.6 (1.9) 1.3 (1.9) 0.9 (1.4)
Table 2 Mean scores and
standard deviations (SDs) of anx-
iety and depression levels by pa-
tients with ovarian tumors and
their partners based on a one-way
MANOVA (n = 251)
Anxiety Depression
Patient Partner p
valuea
η2a Patient Partner p
valuea
η2a
Ovarian cancer 6.0 (3.8) 4.6 (3.6) .01 .03 4.2 (4.3) 4.4 (3.6) .70 < .01
Borderline ovarian
tumor
4.8 (3.4) 4.1 (3.5) .38 .01 3.5 (3.9) 2.7 (2.8) .28 .01
Total 5.6 (3.7) 4.4 (3.6) .01 .03 4.0 (4.2) 3.9 (3.5) .85 < .01
p valueb .12 .55 .46 .01
η2b .02 < .01 < .01 .05
a Compares patient and partner values; p < .025 is significant
b Compares ovarian cancer and borderline ovarian tumor values; p < .025 is significant
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Discussion
Women with an ovarian tumor experience higher anxiety than
their partners, though no significant difference in depressive
symptoms was found. However, the results showed that both
patients with ovarian cancer and their partners experienced
higher levels of anxiety and depression, although this was
only significant for depression in partners. In contrast to our
expectations, positive psychological changes experienced by
either the patient or partner were not associated with their own
or their partner’s anxiety or depression levels.
Contrasting to our results, most other studies examining
anxiety and depression among couples with gynecological
tumors either found no difference between patients and part-
ners on anxiety or depression [34] or found partners suffered
more from distress than patients [8, 9]. These contrasts in
findings may be explained by differences between our study
and earlier studies. First, our study used a population-based
sample, unlike two studies which used a clinical sample [9,
34].
Second, previous studies differ from the current study by
their patient characteristics. One study included multiple can-
cer diagnoses besides gynecological cancer types [34], and
consequently, it was unclear whether variations in anxiety
and depression were attributed to patients with ovarian tu-
mors. Another study exclusively included recovered patients
who survived for more than 5 years since diagnosis [9].
Couples where the patient has been recovered from cancer
have a different foundation for their anxiety and depression
(e.g., dealing with the psychological aftermath of surviving
cancer) from couples in whom the patient is uncertain about
surviving cancer. The current study used a population-based
sample unlike previous studies which used clinical samples.
Furthermore, all studies that reported that partners suffered
from higher or equal levels of negative effect involved non-
European participants [8, 9, 34]. There might be cultural dif-
ferences between Dutch and non-European couples dealing
with ovarian tumors, explaining the dyadic variation in anxi-
ety and depression.
Finally, previous studies performed different analyses,
which did not take into account the possible combined effects
of anxiety and depression. As a result, the current study did
not include the overlap between anxiety and depression but
measured anxiety and depression as separate constructs. We
showed anxiety is the factor that impacts distress.
In line with previous research, we found that ovarian cancer
patients and borderline ovarian tumor patients reported no
differences in anxiety or depression levels [7]. However, we
did observe a trend in higher anxiety and depression levels
among ovarian cancer patients compared to borderline ovarian
tumor patients. These results indicate that even though the
biological prognosis for ovarian cancer is less favorable than
Fig. 2 Estimates and confidence intervals of mutual dyadic association of patients with ovarian tumors and their partners regarding the effect of positive
psychological changes on anxiety and depression. Displayed in brackets are confidence intervals (CIs)
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that for a borderline ovarian tumor, the psychological stress
levels of both types of patients are not so different.
Consistent with our findings, several other studies found no
associations between positive psychological changes and neg-
ative emotions like anxiety and depression [35–37]. A possi-
ble explanation is that experiencing positive psychological
changes and experiencing negative feelings like anxiety and
depression actually are entirely different constructs which co-
exist without influencing each other. After all, someone with a
potentially fatal disease like ovarian cancer can feel more pos-
itive and conscious about one’s self-perception, social rela-
tions, and life perspective due to the disease, while still feeling
anxious and depressed about the possible consequences of the
disease [38]. Another possibility may be that levels of positive
psychological changes, anxiety, and depression fluctuate over
time among survivors. Longitudinal studies are needed to as-
sess changes over time in positive psychological changes,
anxiety, and depression.
Limitations
There are several limitations that should be considered when
interpreting the results of the present study. The sum of the six
positive outcome items of the CaS(P)UNwas used to measure
the positive psychological changes, even though according to
Hodgkinson et al. [27], the positive change items should be
considered separately. To support our approach, we performed
sensitivity analyses on all individual items, showing similar
findings for anxiety and depression as with the sum score. In
retrospect, another questionnaire like the Posttraumatic
Growth Inventory (PTGI) could have been used [39] as PTG
and positive psychological changes are similar constructs.
However, the PTGI and other similar measurements were
not validated among partners of patients diagnosed with can-
cer. As we included partners in our study, we used the
CaS(P)UN questionnaires.
Another limitation of the study is the inclusion of both
women diagnosed with ovarian cancer and women diagnosed
with a borderline ovarian tumor for the second research ques-
tion. Patients with a borderline ovarian tumor were included to
achieve the required amount of participants for proper analy-
ses. The prognosis of borderline ovarian tumor is better than
the prognosis of ovarian cancer due to early diagnoses
resulting in survival rates of 95% 5 years after diagnosis
[40]. Therefore, the experienced anxiety, depression, and pos-
itive psychological changes may be different for patients with
borderline ovarian tumors than for ovarian cancer patients.
However, our study analyses showed no differences between
patients with ovarian cancer and patients with borderline ovar-
ian tumors.
Although for the first research question multicollinearity
between anxiety and depression was taken into account by
performing a MANOVA, for the second research question,
two separate APIM analyses were conducted for anxiety and
depression to analyze the effect of positive psychological
changes. Therefore, anxiety was a potential confounding var-
iable in the model examining the effect of positive psycholog-
ical changes on depression. Similarly, in the model examining
the effect of positive psychological changes on anxiety, de-
pression was a potential confounding variable. We did not add
depression and anxiety as covariates as this might have led to
over-adjustment.
The response percentage of patients ranged between 43 and
57%, while for partners, this ranged from 70 to 30% for ovar-
ian cancer and borderline ovarian tumor, respectively. These
numbers limit the generalizability of our results as, for in-
stance, non-respondents may experience lower quality of life
or worse health compared to respondents.
A final limitation is that respondents were couples who
voluntarily responded to a self-report questionnaire in an un-
controlled setting. Couples could have influenced each other
or could have been influenced by other situational factors
leading to biased responses. Also, only voluntary respondents
were included, whereas there is a possibility anxiety and de-
pression are more or less prevalent among non-respondents.
This may have led to an underrepresentation of anxiety and
depression in couples dealing with ovarian tumors.
Strengths
In spite of several limitations, the current study displayed sev-
eral strengths such as the population-based sampling
supporting generalizability.
Additionally, the current study seemingly is the first study
which incorporated patients with ovarian tumors, their part-
ners, anxiety, depression, and positive psychological changes.
Subsequently, strong analyses were used to analyze (dyadic)
associations between these concepts, including theMANOVA
and APIM procedure.
Furthermore, robust analyses were performed to test the
research questions. The data requested accurate analyses due
to the highly interdependent nature of patient and partner var-
iables. The APIM which was chosen as a measure for the
analyses considers dyadic interdependence while analyzing
the influence of individuals on themselves and on one another
[41]. Similarly, the MANOVA was a strong measure which
took into account the comorbidity between depression and
anxiety.
Implications
It is noteworthy our study found the level of anxiety and
depression for patients and partners surpassed the advised
clinical cutoff scores for cancer patients (HADS-
Depression ≥ 2; HADS-Anxiety ≥ 3) [42]. This confirms
once more that even though patients experience more
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anxiety than partners, distress is a relevant issue for both
patients and partners dealing with ovarian tumors. It is
necessary to inform couples about the possible psycholog-
ical consequences of the diagnosis. As results showed there
were no actor or partner effects of positive psychological
changes on anxiety or depression, couples with ovarian
tumors should be educated that they might experience anx-
iety or depression besides positive psychological changes
after diagnosis. Moreover, couples should have access to
psycho-education about the differences and similarities in
anxiety and depression experienced by patients and part-
ners to better understand each other. Further research could
explore which dyadic mechanisms could influence anxiety
and depression in ovarian tumor patients and partners and
which dyadic interventions might be appropriate to support
both patients and partners.
Conclusion
The present study showed that patients diagnosed with ovar-
ian tumors suffer more from anxiety than their partners,
though no difference on depression was found. There may
be a trend that ovarian cancer patients and their partners ex-
perience higher levels of anxiety and depression than patients
with a borderline ovarian tumor and their partners, although
differences are small and only significant for depression ex-
perienced by partners. Positive psychological changes experi-
enced by patients and partners were not associated with anx-
iety or depression of patient or partner, indicating positive
psychological changes have no effect on distress. As patients
and partners had elevated levels of anxiety and depression,
couples dealing with ovarian tumors should have access to
supportive care to deal with their distress levels. Future re-
search should assess whether dyadic interventions are
appropriate.
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